Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Humana Inc (NYSE: HUM) closed the day trading at $299.51 up 1.71% from the previous closing price of $294.47. In other words, the price has increased by $1.71 from its previous closing price. On the day, 1.62 million shares were traded. HUM stock price reached its highest trading level at $301.405 during the session, while it also had its lowest trading level at $295.96.
Ratios:
For a better understanding of HUM, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.69.
On November 06, 2024, BofA Securities Upgraded its rating to Neutral which previously was Underperform and also upped its target price recommendation from $247 to $308.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 14 ’25 when Rechtin James A. bought 6,530 shares for $229.25 per share. The transaction valued at 1,496,984 led to the insider holds 30,474 shares of the business.
Diamond Susan M bought 10,959 shares of HUM for $2,732,134 on Apr 08 ’25. On Feb 24 ’25, another insider, Huval Timothy S., who serves as the Former Chief Administrative Of of the company, bought 1,247 shares for $258.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUM now has a Market Capitalization of 36022669312 and an Enterprise Value of 27296612352. As of this moment, Humana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.99, and their Forward P/E ratio for the next fiscal year is 21.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29 while its Price-to-Book (P/B) ratio in mrq is 1.98. Its current Enterprise Value per Revenue stands at 0.222 whereas that against EBITDA is 6.799.
Stock Price History:
The Beta on a monthly basis for HUM is 0.42, which has changed by -0.15152973 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, HUM has reached a high of $382.72, while it has fallen to a 52-week low of $206.87. The 50-Day Moving Average of the stock is 20.65%, while the 200-Day Moving Average is calculated to be 14.68%.
Shares Statistics:
Over the past 3-months, HUM traded about 1.74M shares per day on average, while over the past 10 days, HUM traded about 1543610 shares per day. A total of 120.27M shares are outstanding, with a floating share count of 119.99M. Insiders hold about 0.23% of the company’s shares, while institutions hold 95.46% stake in the company. Shares short for HUM as of 1753920000 were 4682779 with a Short Ratio of 2.70, compared to 1751241600 on 4322192. Therefore, it implies a Short% of Shares Outstanding of 4682779 and a Short% of Float of 4.37.
Dividends & Splits
HUM’s forward annual dividend rate is 3.54, up from 3.54 a year ago. Against a Trailing Annual Dividend Yield of 0.012021598The stock’s 5-year Average Dividend Yield is 0.82. The current Payout Ratio is 35.45% for HUM, which recently paid a dividend on 2025-06-27 with an ex-dividend date of 2025-09-26. Stock splits for the company last occurred on 1991-08-01 when the company split stock in a 3:2 ratio.
Earnings Estimates
The firm’s stock currently is rated by 22.0 analysts. The consensus estimate for the next quarter is -$3.74, with high estimates of -$2.74 and low estimates of -$4.43.
Analysts are recommending an EPS of between $17.26 and $16.18 for the fiscal current year, implying an average EPS of $16.93. EPS for the following year is $13.63, with 24.0 analysts recommending between $15.85 and $10.42.
Revenue Estimates
15 analysts predict $31.98B in revenue for the current quarter. It ranges from a high estimate of $32.2B to a low estimate of $31.4B. As of the current estimate, Humana Inc’s year-ago sales were $29.4BFor the next quarter, 15 analysts are estimating revenue of $31.85B. There is a high estimate of $32.38B for the next quarter, whereas the lowest estimate is $31.07B.
A total of 18 analysts have provided revenue estimates for HUM’s current fiscal year. The highest revenue estimate was $129.03B, while the lowest revenue estimate was $126.97B, resulting in an average revenue estimate of $128.18B. In the same quarter a year ago, actual revenue was $117.76BBased on 18 analysts’ estimates, the company’s revenue will be $134.39B in the next fiscal year. The high estimate is $145.97B and the low estimate is $121.6B.
